- Home
- BSM vs SUPN Comparison
BSM vs SUPN Comparison
Compare BSM & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BSM | SUPN |
|---|---|---|
| Founded | 1876 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.8B |
| IPO Year | 2015 | 2010 |
Fundamental Metrics
Financial Performance| Metric | BSM | SUPN |
|---|---|---|
| Price | $14.14 | $51.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $14.00 | ★ $61.60 |
| AVG Volume (30 Days) | 413.3K | ★ 493.5K |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | ★ 8.46% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $469,919,000.00 | $392,755,000.00 |
| Revenue This Year | $13.19 | $22.72 |
| Revenue Next Year | $10.45 | $18.10 |
| P/E Ratio | $12.82 | ★ N/A |
| Revenue Growth | ★ 8.35 | N/A |
| 52 Week Low | $11.90 | $29.16 |
| 52 Week High | $15.49 | $59.68 |
Technical Indicators
Market Signals| Indicator | BSM | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 30.79 | 54.45 |
| Support Level | $13.07 | $47.43 |
| Resistance Level | $15.33 | $52.25 |
| Average True Range (ATR) | 0.32 | 1.62 |
| MACD | -0.13 | 0.23 |
| Stochastic Oscillator | 10.87 | 85.58 |
Price Performance
Historical ComparisonAbout BSM Black Stone Minerals L.P.
Black Stone Minerals LP is an oil and natural gas mineral company. It owns oil and natural gas mineral interests, which makes up the majority of its asset base. Its business is actively managing an existing portfolio of mineral and royalty assets to maximize its value and expanding asset base through acquisitions of additional mineral and royalty interests. The company owns mineral interests in approximately 16.9 million gross acres.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.